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 Introduction 
 Integrating imaging into clinical practice is an impor-
tant challenge for physicians treating inflammatory bow-
el disease (IBD) patients. This is a special case as there has 
been a change in the view of how clinical practice in IBD 
management should ideally be. Whereas the clinical dis-
ease presentation and clinical symptom control had been 
the main focus in IBD treatment in the past years and the 
treatment was aimed at achieving a symptom free situa-
tion for the patient, new treatment goals and paradigms 
have entered treatment algorithms in IBD. Mucosal or 
even histological healing, ‘sustained deep remission’, 
‘treat to target’ and ‘target to achieve’ are new terms that 
have been introduced in discussions regarding the man-
agement of IBD patients (partially without sufficient evi-
dence from clinical trials). These new treatment goals 
have changed the focus about the optimal monitoring of 
disease activity and, therefore, subsequently have also 
changed the recommendations for imaging during the 
course of IBD. At present, we face important discussions 
about when and how often to apply imaging techniques 
in IBD patients. This is further complicated by the fact 
that several imaging techniques are available only in cer-
tain countries. In North America and Great Britain, CT 
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 Abstract 
 Imaging is an important component for the monitoring of 
therapeutic success and disease control in patients with IBD. 
Colonoscopy is still the gold standard for imaging of disease 
activity. It is questionable, however, whether ‘standard’ or 
‘routine’ imaging procedures max contribute to improved 
IBD therapy. There are good arguments for a problem driven 
imaging approach in IBD. Subsequently, the schedule of 
monitoring examinations should depend on the disease 
course (mild vs. severe) and the treatment used. Bowel ultra-
sound where available may substitute for endoscopy in 
many circumstances. New endoscopic techniques will be 
available at specialized centers for specific management 
questions. Applying these individualized strategies, imag-
ing/monitoring will pay off for better disease control and 
better quality of life for IBD patients in the future. 
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scans are much easily available as compared to MRI. In 
contrast, in Central Europe, MRI is preferred as com-
pared to CT scans and further developed with new evalu-
ation software. In addition, in several European coun-
tries, ultrasonography (US) has become a standard tech-
nique for monitoring the IBD patients whereas in other 
countries such as the United States, it is only in the hand 
of radiologists making it difficult to be applied for moni-
toring the IBD patients. In the following article, the future 
of imaging and monitoring in IBD is discussed from a 
viewpoint rather derived by personal clinical experience 
than robust and prospective clinical evidence, that is, on 
a comparable ground work as most of the current litera-
ture on mucosal healing and treat to target.
 When Do We Need Imaging Tools for IBD Patients? 
 Usually, the first time imaging is used – or at last 
should be used – in a suspected case of IBD is when the 
occurring symptoms can be associated with the disease 
( fig. 1 ). Imaging is used for confirming the diagnosis and 
 Fig. 1. Development of CD over time. Different clinical situations (gray) require diagnostic procedures and dis-
ease monitoring. The purpose of why such procedures will be necessary or undertaken is coded in green. The 
different diagnostic procedures performed to answer the clinical questions are in the red fields. 
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for differential diagnosis  [1] . Still, we do not have a gold 
standard for diagnostic procedures in Crohn’s disease 
(CD) and ulcerative colitis (UC). Most guidelines, how-
ever, for example the ECCO guidelines  [1] , clearly state 
that endoscopy should be the basis of diagnosis ( fig. 1 ). 
In CD, further imaging techniques, such as US and MRI 
or CT scans, are highly valuable for evaluating the small 
bowel  [1] . Indeed, performing a small bowel evaluation 
with one of the aforementioned diagnostic tools is ex-
plicitly recommended in every initial diagnostic proce-
dure to establish the diagnosis of CD, irrespective of the 
findings by ileocolonoscopy, according to the ECCO 
guidelines  [2] . Imaging techniques can also help in the 
evaluation of the prognosis, the risk for complications 
and provide guidance regarding the initial treatment op-
tions  [3–7] ( fig. 1 ). Whereas this is not very much dis-
puted, the indication and schedule for further imaging 
during fluctuating disease activity is much more prone 
to controversies. If clinical symptoms are not sufficient 
to evaluate the success of therapy, and at the time when 
a status of being free of clinical symptoms is not accept-
ed anymore as the treatment goal of IBD therapy, other 
parameters obviously must play a more important role. 
Mucosal healing of course can only be evaluated by tak-
ing a look at the mucosa and in fact only by taking mu-
cosal biopsies  [8, 9] . It is disputable whether deep remis-
sion can also be evaluated by other imaging technics 
such as US and MRI or CT scan  [9] . In this respect, an 
interesting and elegant investigation (yet only published 
in abstract form) comparing 2 evaluation strategies in 
CD providing, at first, the results of endoscopy and, sub-
sequently, findings of MRI to 4 clinical expert investiga-
tors for the procedure the other way round, revealed that 
the results of MRI harbored a higher impact on subse-
quent clinical decision making than those of colonos-
copy, thus directly challenging colonoscopy’s current 
pole position in the diagnostic algorithm of CD  [10] . 
Eventually, assuming one would assign an even higher 
importance to histological healing as compared to mu-
cosal healing derived by pure vision, the role of assess-
ment by both endoscopy and imaging to adjust treat-
ment or predict relapse risk may be challenged by com-
parative investigations with fecal calprotectin, suggesting 
that the correlation of the latter to histological healing 
may even surpass endoscopy. If we define a necessity to 
assess disease activity with such techniques, another 
point of discussion is about how often we should moni-
tor disease activity. This subsequently leads to a point of 
concern about the frequency of evaluation of treatment 
success.
 Concepts That Propose a Frequent Evaluation of 
Therapy Success 
 In recent years, several concepts have pointed to an 
increased requirement of evaluation of disease activity by 
imaging. Among those are the concepts of mucosal heal-
ing, ‘sustained deep remission’, ‘treat to target’ and ‘target 
to achieve’. In a recent publication by the International 
Organization for the Study of Inflammatory Bowel Dis-
eases, the authors state the following: ‘Collectively, these 
data suggest that an ideal treat-to-target strategy should 
follow the patient every 36 months for assessment of MH 
(disappearance of ulcers) with colonoscopy (or MRE or 
US in patients who cannot be adequately assessed with 
colonoscopy). … Six-month intervals between colonos-
copy procedures may be a reasonable compromise be-
tween selecting a time after which additional MH is un-
likely to occur and a time interval between procedures 
that would be acceptable to patients’  [11] . This obviously 
means that after a change in therapy, at least every 
6 months, a colonoscopy should be performed to evaluate 
whether this change in therapy has been successful. One 
of the reasons to suggest this is that it appears to be ac-
ceptable for the patients. Potential acceptance by the pa-
tients may not be a perfectly robust argument to define 
the intervals for a diagnostic imaging procedure. Either it 
is necessary or it is not. If it is necessary, but not accepted 
by the patients, we have to find an alternative method. 
Also, the time between the change of therapy and the 
evaluation by endoscopy seems to be somewhat arbitrary, 
for instance, different treatments obviously have different 
response times. An anti-integrin or anti-metabolite ther-
apy will take more time for response as compared to a 
therapy using antibodies to tumor necrosis factor. Subse-
quently, it appears to be obvious that the selection of the 
imaging modality and the interval between the treatment 
change and the imaging procedure should be dependent 
on the therapy that is chosen.
 Furthermore, it is doubtful whether patients would ac-
cept an imaging/disease monitoring strategy as outlined 
in  figure 2 . In contrast, it rather appears that this simply 
would and will not be practicable.
 In contrast, in a recent manuscript by Bouguen et al. 
 [12] , the authors conclude that ‘repeated assessment of 
endoscopic disease activity with adjustment of medical 
therapy to the target of mucosal healing is feasible in clin-
ical practice in patients with UC, and seems to be of ben-
efit’. Of course, endoscopic assessment is much easier in 
patients with UC as usually no complete colonoscopy is 
necessary. The question, however, is whether repetitive 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
5/
27
/2
01
6 
11
:4
5:
31
 A
M
 Rogler/Vavricka/Biedermann  Dig Dis 2015;33(suppl 1):37–43 
DOI: 10.1159/000437063
40
calprotectin measurements could replace endoscopies as 
it is well known and evident from published literature 
that calprotectin correlates to histology even better than 
endoscopic evaluation in patients with UC  [13–15] . In the 
60 patients included in this retrospective analysis men-
tioned above, 159 endoscopic procedures were performed 
including 92 ileocolonoscopies and 67 flexible sigmoid-
oscopies  [12] . Less than 50% of the patients included had 
3 consecutive endoscopic procedures, and only 8 had 4 
consecutive endoscopic procedures  [12] . It is doubtful 
whether from those selected patient with a majority of 
only 2 endoscopic procedures, it can be concluded that 
repeated endoscopic control of mucosal healing or ther-
apy success is really feasible  [12] .
 Another publication from the same authors concluded 
that regular endoscopic assessment of mucosal healing 
and endoscopic disease activity and subsequent adjust-
ments of medical therapy increased the likelihood of mu-
cosal healing  [11] . Again, this was a retrospective study 
with some risk of selection bias. After a median follow-up 
period of 62 weeks in the included 67 patients (out of 161 
that had at least 2 endoscopies), a total of 161 endoscopic 
procedures were performed, including 151 ileocolonos-
copies or flexible sigmoidoscopies. Only 31% underwent 
3 consecutive endoscopic procedures, and only 6 patients 
(9%) underwent 4 consecutive endoscopic procedures 
 [11] . Similar to UC patients, it appears to be doubtful 
whether it can be concluded that repetitive endoscopy is 
feasible, from these data, in the long-term treatment of 
CD patients ( fig.  2 ). Furthermore, endoscopy has not 
been compared to other strategies of monitoring of ther-
apy success such as calprotectin or US  [4, 16, 17] .
 US Allows Frequent Evaluation of Therapy Success 
 US techniques have long been used for the monitoring 
of therapy success in patients with UC and CD. US has a 
number of advantages such as transmural evaluation of 
the bowel wall (in contrast to endoscopy and similar to 
CT/MRI), rapid information without delay or prepara-
tion (in contrast to endoscopy, MRI or CT scan, e.g. with 
 Fig. 2. Imaging and monitoring as suggest-
ed mainly by endoscopy-focused gastroen-
terologists. Patients may not accept such a 
strategy. 
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the question: ‘does a change of symptoms reflect a flare?’), 
no X-ray exposure (in contrast to CT scans, similar to 
MRI), evaluation of motility (live on-site in contrast to 
endoscopy, CT scan and MRI, which is important to eval-
uate functional impairment), the possibility of evaluating 
patient history and symptoms in parallel (e.g. ‘where/
there is the maximum of pain?’) ( table 1 ). In contrast to 
the frequent notion that US is a very subjective method, 
there are objective parameters in bowel US, and an assess-
ment of these should be requested ( table 1 ). Bowel wall 
thickness at least in certain segments can be objectively 
quantified and reliably monitored. Therefore, it can be 
used as a parameter of therapy success. The relevance of 
measuring bowel wall thickness has been demonstrated 
by a number of studies, and sensitivities of 75–94% and 
specificities of 67–100% have been reported  [1] . As out-
 Fig. 3. Individualized, patient- and situa-
tion-adapted strategy for imaging and dis-
ease monitoring as suggested in this manu-
script. 
Table 1.  Imaging modalities in IBD
Endoscopy US CT MRI
Mucosa +++ ++ ++ ++
Transmural – +++ +++ +++
Fistula + ++ +++ ++++
Abscess – ++ +++ +++
Strictures ++ +++ +++ +++
Operator department + ++ + +
Standardized images + + ++++ ++++
Irradiation no no yes no
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lined in the ECCO consensus on imaging, a recent meta-
analysis of 7 prospective, well-designed diagnostic trials 
indicated that a threshold of >3 mm bowel wall thickness 
as cut-off value possesses a sensitivity and specificity 88 
and 93%, respectively, for acute inflammation in CD, 
while a cut-off level of >4 mm is associated with a sensi-
tivity and specificity of 75 and 97%, respectively  [18] .
 Subsequently, the ECCO guidelines on imaging state 
that ‘US, CT and MRI have a high and comparable diag-
nostic accuracy at the initial presentation of terminal il-
eal CD’ (statement 3A)  [1] . They further explain that ‘US, 
CT, MRI and white blood cell scintigraphy can be used to 
assess disease activity in CD of the terminal ileum’ (state-
ment 3B)  [1] . Also, for monitoring purposes, US is re-
garded to be useful as outlined in statement 4B: ‘transab-
dominal US and MRI have a high accuracy for assessing 
the activity and severity of Crohn’s colitis (EL:1b, RG:A); 
the performance in UC is less clear and the role of CT for 
distinguishing quiescent from active colonic IBD is cur-
rently not defined’  [1] . Subsequently, US in combination 
with calprotectin values (which will not be discussed here 
as this is out of the focus of this article) may perfectly 
complement and indeed at least frequently well replace 
endoscopy in the suggested tight monitoring of therapy 
success and respective adjustments in IBD patients 
( fig. 3 ).
 Summary 
 Imaging for the monitoring of therapeutic success and 
disease control (or ‘mucosal healing’) will be an essential 
component of future IBD patient care. However, imaging 
should be problem driven (‘is there a question to an-
swer?’; ‘will the results of imaging change treatment?’), 
and not strict and rigid as it is on regular basis as sug-
gested by some recent publications. Furthermore, the 
schedule of monitoring examinations should depend on 
the disease course (mild vs. severe) and the treatment 
used (e.g. antibodies to tumor necrosis factor therapies 
versus anti-integrin antibodies). US may substitute for 
endoscopy in many instances for the monitoring of IBD 
patients ( fig. 3 ). New endoscopic techniques may be avail-
able at specialized centers for specific management ques-
tions; however, they will not reach a general distribution 
in the foreseeable future. Applying these strategies, imag-
ing/monitoring will pay off for better disease control and 
better quality of life for IBD patients in the future.
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